## 3 Results  
### Safety Control of LPa 12/1 Strain  
No mortality was noted in mice during the safety control experiment. On day 30, the count of LPa 12/1 strain in faeces reached 3.64 \(\pm\) 0.56 cfu/g (log 10). This colonization was sufficient. On day 45 (15 days of LPa 12/1 strain cessation), a decrease in LPa12/1 strain was noted (\(p\) < 0.01). The LPa 12/1 strain contributed to the total LAB increase in faeces on day 30 (difference 0.59 log cycle) and day 45 (\({}^{\text{ab}}\)\(p\) < 0.001) compared with day 0/1. Faecal (amyloidytic) streptococci were present in high counts (Table 1). The coliform count was significantly reduced in the experimental group on day 30 (30 EG) compared with the experimental group on day 45--45 EG (\({}^{\text{ab}}\)\(p\) < 0.05). In the jejunum, the LPA 12/1 strain count was lower than in the faeces (Table 2). It reached up to 10\({}^{2}\) cfu/g on day 30. On day 45, it reduced by almost up to 10\({}^{1}\) cfu/g (Table 2). The total LAB count in the jejunum was high and not reduced, as well as the counts of streptococci (Table 2). The coliforms were detected in the jejunum in counts commonly determined in animal jejunum; however, they were slightly mathematically reduced, with a difference of 0.74 log cycles. In the liver, LPa 12/1 reached 1.30 \(\pm\) 0.0 cfu/g (log 10). On day 45, its count decreased (less than 0.1 cfu/g). The LAB count reached 4.23 \(\pm\) 0.5 cfu/g, which means the strain probably contributed to the total LAB count because a decrease was noted on day 45 (2.42 \(\pm\) 0.55 cfu/g Table 3). Streptococci were counted up to 10\({}^{2}\) cfu/g, and they were mathematically reduced with a difference of 0.58 log cycles comparing day 30 and day 45. In the liver, the counts of coliforms were low and not influenced. \begin{table}
\begin{tabular}{c c c c c} \hline
**Faeces** & **LPa 12/1** & **LAB** & **Amyl. Str.** & **Coliforms** \\ \hline Sampling 0/1 (\(n\) = 8) & nt & 5.48 \(\pm\) 0.52 a & 5.49 \(\pm\) 0.07 & 3.27 \(\pm\) 0.49 \\ \hline Sampling 30 EG (\(n\) = 5) & 3.64 \(\pm\) 0.56 a & 6.07 \(\pm\) 0.07 d & 5.16 \(\pm\) 0.30 a & 4.66 \(\pm\) 0.59 a \\ \hline Sampling 30 CG & nt & 6.47 \(\pm\) 0.51 & 5.04 \(\pm\) 0.47 & 5.08 \(\pm\) 0.42 \\ \hline Sampling 45 EG & 2.62 \(\pm\) 0.61 b & 7.04 \(\pm\) 0.15 b & 5.59 \(\pm\) 0.04 & 3.76 \(\pm\) 0.44 b \\ \hline Sampling 45 CG & nt & 7.1 \(\pm\) 0.0 c & 6.05 \(\pm\) 0.18 b & 2.28 \(\pm\) 0.33 \\ \hline Sampling 0/1, sampling before LPa 12/1 strain application; sampling 30 EG and 30 CG, sampling at day 30 in the experimental and control groups; Sampling 45 EG and 45 CG, sampling at day 45 in the experimental and control groups; LPA 12/1, \({}^{\text{ab}}\)\(p\)\(<\) 0.01; LAB-lactic acid bacteria, ab,ac \(p\)\(<\) 0.001, ab \(p\)\(<\) 0.01; amylolytic streptococci, ab \(p\)\(<\) 0.05; coliforms, ab \(p\)\(<\) 0.05; day 30—30 day application of LPa 12/1, day 45, 15 days of LPa 12/1 cessation; nt—not tested. & & \\ \end{tabular}
\end{table} 
Table 1: The LPa 12/1 counts and controlled selected microbiota in faeces of Balb/c mice after strain application and its cessation. \begin{table}
\begin{tabular}{c c c c c} \hline
**\(n\) = 5** & **LPa 12/1** & **LAB** & **Amyl. Str.** & **Coliforms** \\ \hline Sampling 30 EG & 1.70 \(\pm\) 1.30 & 6.03 \(\pm\) 0.07 & 4.54 \(\pm\) 0.11 & 5.33 \(\pm\) 0.53 \\ \hline Sampling 30 CG & nt & 6.04 \(\pm\) 0.07 & 4.15 \(\pm\) 0.52 & 6.07 \(\pm\) 0.06 \\ \hline Sampling 45 EG & 0.72 \(\pm\) 0.08 & 6.04 \(\pm\) 0.10 & 5.51 \(\pm\) 0.3 & 5.96 \(\pm\) 0.50 \\ \hline Sampling 45 CG & nt & 6.47 \(\pm\) 0.58 & 5.13 \(\pm\) 0.21 & 5.71 \(\pm\) 0.33 \\ \hline Sampling 0/1, sampling before LPa 12/1 strain application; Sampling 30 EG and 30 CG, sampling at day 30 in the experimental and control groups; Sampling 45 EG and 45 CG, sampling at day 45 in the experimental and control groups; coliforms, on day 30 (mathematical difference 0.74 log cycle); day 30—30 days application of LPa 12/1, day 45, 15 days of LPa 12/1 cessation, nt—not tested. & & \\ \end{tabular}
\end{table}